Skip to Content

Vaccex Inc VCEX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Vaccex Inc is a development stage biotechnology company. The company is focused on developing and commercializing immunotherapy products. Its product (VX001) is a sustained-release formulation of a potent TLR7/8 agonist that works in synergy with fractionated radiotherapy (RT). VX001 is a potent stimulator of the innate immune system and intratumoral injection of VX001 in combination with RT causes tumor regression, long-term survival and prevention of cancer upon re-challenges in syngenic mouse models.

Contact
6 Liberty Square, Suite 2381
Boston, MA, 02109
T +1 452 081-5802
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2020
Stock Type
Employees